

INTRASENSE WINS A FIRST STUDY WITH A LEADING JAPANESE IMAGING CRO

Micron to utilize Myrian® solution in MRI imaging trial

Paris (France), November 19, 2013: Intrasense, a global leader in multimodal medical imaging software, announces the use of its software suite Myrian® by Micron Inc., a leading Japanese imaging CRO, in MRI imaging trial.

Contract Research Organizations (CRO) spearhead many of the clinical research projects, monitoring the results to provide more efficient, effective diagnosis and analysis of various medical treatments. Japan is one of the leading countries in this respect and Micron Inc., one of Asia's leading imaging CROs will initiate a study involving MRI imaging starting in December 2013. After extensive evaluation tests on Intrasense's solution, Micron has selected Myrian® software and its clinical modules, thus strengthening Intrasense's international presence on the field of clinical trials.

Micron is providing imaging services from non-clinical areas through all phases of clinical studies. A well-established firm, Micron has a long-standing reputation as an innovator and leader in the field of standardizing image acquisition techniques for robust and reliable image reading. In the area of clinical development, Micron specializes in monitoring, quality control, image handling and analysis with a key competitive advantage in its ability to handle multimodality imaging.

Micron's CEO Makoto Sato notes that *"Micron's image and reputation has been recognized by many pharmaceutical companies for its ability to provide a global standard of quality and performance in imaging clinical trials. We look forward to utilizing the Myrian® solution in helping to conduct our imaging studies."*

Japan is the most active Asian country in the field of clinical research and it is very significant to deploy Myrian® in this region. According to Patrick Mayette, Intrasense's CEO, *"This new business relationship continues our expansion in the clinical research market and further highlights Myrian®'s multi-therapeutic and multimodality capabilities as a strong differentiator to serve the CRO market."*

About Micron Inc. (Molecular Imaging CRO Network):

Micron Inc. (CEO: Makoto Sato, headquarters: Chiyoda-ku, Tokyo, Japan) has established an environment to implement many multicenter imaging clinical trials, especially in Asian countries, such as Japan and Korea. Micron excels in standardizing image acquisition techniques, ensuring high quality of image collection for reliable image reading, and smooth imaging clinical trial operations based on accumulated know-how. As an imaging CRO, Micron's performance has been recognized by many pharmaceutical companies with a lot of imaging clinical trials complying with global standard quality.

For more about Micron, please visit: www.micron-kobe.com.

About Intrasense:

Intrasense designs, develops and markets Myrian[®], a unique, proven software suite for the visualization and advanced processing of multimodal medical images (MRI, CT scans, PET, X-rays and more). Developed with leading academic and scientific partners, Myrian[®] combines and uses all medical images modalities to extract vital information for patients' care; for rapid evaluation of the efficiency of treatment; and, to assess drug candidates in oncology and other pathologies. With more than 700 client sites around the world, Myrian[®] has been certified as a "medical device" in over 40 countries including the United States (FDA), Europe (CE) and Asia. Intrasense SA is listed on the NYSE Alternext (FR0011179886 - ALINS).

For more about Intrasense, please go to our website: www.intrasense.fr.

CONTACTS**Intrasense**

Patrick Mayette

CEO

Christophe Lamboeuf

Chief Financial Officer

Phone : +33(0)1 48 04 32 83

investisseurs@intrasense.fr**NewCap.**

Financial Communication and Investor

Relations

Valentine Brouchet / Pierre Laurent

Phone : +33(0)1 44 71 98 52

intrasense@newcap.fr**ALINS**
LISTED
NYSE
ALTERNEXT